Undifferentiated Wharton’s jelly mesenchymal stem cell transplantation induces insulin-producing cell differentiation and suppression of T-cell-mediated autoimmunity in nonobese diabetic mice

Cell Transplantation

Volumn 24, Issue 8, 2015, Pages 1555-1570

  Tsai, Pei Jiun ^a,b   Wang, Hwai Shi ^a   Lin, Gu Jiun ^c   Chou, Shu Cheng ^b   Chu, Tzu Hui ^c   Chuan, Wen Ting ^c   Lu, Ying Jui ^c   Weng, Zen Chung ^d,e   Su, Cheng Hsi ^f   Hsieh, Po Shiuan ^c   Sytwu, Huey Kang ^c   Lin, Chi Hung ^a   Chen, Tien Hua ^b   Shyu, Jia Fwu ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Immunomodulation; Insulin producing cells (IPCs); Mesenchymal stem cells (MSCs); NOD mice; Wharton s jelly

Indexed keywords

C PEPTIDE; GLUCOSE; GREEN FLUORESCENT PROTEIN; INSULIN; INTERLEUKIN 17; LENTIVIRUS VECTOR; SODIUM CHLORIDE; CYTOKINE; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULITIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINUS VENOSUS; SURVIVAL RATE; T LYMPHOCYTE; TH1 CELL; ANALYSIS; ANIMAL; AUTOIMMUNITY; BLOOD; CELL CULTURE; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; GENETICS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; PATHOLOGY; WHARTON JELLY;

MUS;

ANIMALS; AUTOIMMUNITY; BLOOD GLUCOSE; C-PEPTIDE; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; SURVIVAL RATE; T-LYMPHOCYTES; WHARTON JELLY;

EID: 84938868741     PISSN: 09636897     EISSN: 15553892     Source Type: Journal    
DOI: 10.3727/096368914X683016     Document Type: Article

References (52)

1. Anzalone, R.; Lo Iacono, M.; Corrao, S.; Magno, F.; Loria, T.; Cappello, F.; Zummo, G.; Farina, F.; La Rocca, G. New emerging potentials for human Wharton’s jelly mesenchymal stem cells: Immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev. 19(4):423–438; 2010.
2. Anzalone, R.; Lo Iacono, M.; Loria, T.; Di Stefano, A.; Giannuzzi, P.; Farina, F.; La Rocca, G. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: Extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev. 7(2):342–363; 2011.
3. Augello, A.; Tasso, R.; Negrini, S. M.; Cancedda, R.; Pennesi, G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56(4):1175–1186; 2007.
4. Azar, S. T.; Tamim, H.; Beyhum, H. N.; Habbal, M. Z.; Almawi, W. Y. Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Clin. Diagn. Lab. Immunol. 6(3):306–310; 1999.
5. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y. J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767–811; 2000.
6. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature 392(6673):245–252; 1998.
7. Bongso, A.; Fong, C. Y. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev. 9(2):226–240; 2013.
8. Boomsma, R. A.; Swaminathan, P. D.; Geenen, D. L. Intravenously injected mesenchymal stem cells home to viable myocardium after coronary occlusion and preserve systolic function without altering infarct size. Int. J. Cardiol. 122(1):17–28; 2007.
9. Bour-Jordan, H.; Salomon, B. L.; Thompson, H. L.; Szot, G. L.; Bernhard, M. R.; Bluestone, J. A. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J. Clin. Invest. 114(7):979–987; 2004.
10. Bouwens, L.; Houbracken, I.; Mfopou, J. K. The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat. Rev. Endocrinol. 9:598–606; 2013.
11. Cameron, M. J.; Arreaza, G. A.; Zucker, P.; Chensue, S. W.; Strieter, R. M.; Chakrabarti, S.; Delovitch, T. L. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159(10):4686–4692; 1997.
12. Casiraghi, F.; Azzollini, N.; Cassis, P.; Imberti, B.; Morigi, M.; Cugini, D.; Cavinato, R. A.; Todeschini, M.; Solini, S.; Sonzogni, A.; Perico, N.; Remuzzi, G.; Noris, M. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181(6):3933– 3946; 2008.
13. Chao, K. C.; Chao, K. F.; Fu, Y. S.; Liu, S. H. Islet-like clusters derived from mesenchymal stem cells in Wharton’s jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One 3(1):e1451; 2008.
14. Christodoulou, I.; Kolisis, F. N.; Papaevangeliou, D.; Zoumpourlis, V. Comparative evaluation of human mesenchymal stem cells of fetal (Wharton’s jelly) and adult (adipose tissue) origin during prolonged in vitro expansion: Considerations for cytotherapy. Stem Cells Int. 2013:246-134; 2013.
15. Corrao, S.; La Rocca, G.; Lo Iacono, M.; Corsello, T.; Farina, F.; Anzalone, R. Umbilical cord revisited: From Wharton's jelly myofibroblasts to mesenchymal stem cells. Histol. Histopathol. 28(10):1235–1244; 2013.
16. Emamaullee, J. A.; Davis, J.; Merani, S.; Toso, C.; Elliott, J. F.; Thiesen, A.; Shapiro, A. M. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58(6):1302–1311; 2009.
17. Ezquer, F.; Ezquer, M.; Contador, D.; Ricca, M.; Simon, V.; Conget, P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore TH1/TH2 balance and to modify the pancreatic microenvironment. Stem Cells 30(8):1664–1674; 2012.
18. Fiorina, P.; Jurewicz, M.; Augello, A.; Vergani, A.; Dada, S.; La Rosa, S.; Selig, M.; Godwin, J.; Law, K.; Placidi, C; Smith, R. N.; Capella, C.; Rodig, S.; Adra, C. N.; Atkinson, M.; Sayegh, M. H.; Abdi, R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J. Immunol. 183(2):993–1004; 2009.
19. Fiorina, P.; Voltarelli, J.; Zavazava, N. Immunological applications of stem cells in type 1 diabetes. Endocr. Rev. 32(6):725–754; 2011.
20. Godfrey, K. J.; Mathew, B.; Bulman, J. C.; Shah, O.; Clement, S.; Gallicano, G. I. Stem cell-based treatments for Type 1 diabetes mellitus: Bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabet. Med. 29(1):14–23; 2012.
21. Gonzalez, M. A.; Gonzalez-Rey, E.; Rico, L.; Buscher, D.; Delgado, M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 60(4):1006–1019; 2009.
22. Gregori, S.; Giarratana, N.; Smiroldo, S.; Adorini, L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171(8):4040– 4047; 2003.
23. Hu, J.; Yu, X.; Wang, Z.; Wang, F.; Wang, L.; Gao, H.; Chen, Y.; Zhao, W.; Jia, Z.; Yan, S; Wang, Y. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr. J. 60(3):347–357; 2013.
24. Karahuseyinoglu, S.; Cinar, O.; Kilic, E.; Kara, F.; Akay, G. G.; Demiralp, D. O.; Tukun, A.; Uckan, D.; Can, A. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells 25(2):319–331; 2007.
25. Koarada, S.; Wu, Y.; Olshansky, G.; Ridgway, W. M. Increased nonobese diabetic Th1:Th2 (IFN-gamma:IL-4) ratio is CD4+ T cell intrinsic and independent of APC genetic background. J. Immunol. 169(11):6580–6587; 2002.
26. Kuriya, G.; Uchida, T.; Akazawa, S.; Kobayashi, M.; Nakamura, K.; Satoh, T.; Horie, I.; Kawasaki, E.; Yamasaki, H.; Yu, L.; Iwakura, Y.; Sasaki, H.; Nagayama, Y.; Kawakami, A.; Abiru, N. Double deficiency in IL-17 and IFN-gamma signalling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia 56(8):1773–1780; 2013.
27. La Rocca, G.; Anzalone, R. Perinatal stem cells revisited: Directions and indications at the crossroads between tissue regeneration and repair. Curr. Stem Cell Res. Ther. 8(1):2–5; 2013.
28. La Rocca, G.; Corrao, S.; Lo Iacono, M.; Corsello, T.; Farina, F.; Rita Anzalone, R. Novel immunomodulatory markers expressed by human WJ-MSC: An updated review in regenerative and reparative medicine. Open Tissue Eng. Regen. Med. J. 5:50–58; 2012.
29. La Rocca, G.; Lo Iacono, M.; Corsello, T.; Corrao, S.; Farina, F.; Rita Anzalone, R. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: New perspectives for cellular therapy. Curr. Stem Cell Res. Ther. 8(1):100–113; 2013.
30. Leitao, C. B.; Cure, P.; Tharavanij, T.; Baidal, D. A.; Alejandro, R. Current challenges in islet transplantation. Curr. Diab. Rep. 8(4):324–331; 2008.
31. Liblau, R. S.; Singer, S. M.; McDevitt, H. O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16(1):34–38; 1995.
32. Liu, X.; Wang, Y.; Li, Y.; Pei, X. Research status and prospect of stem cells in the treatment of diabetes mellitus. Sci. China Life Sci. 56(4):306–312; 2013.
33. Madec, A. M.; Mallone, R.; Afonso, G.; Abou Mrad, E.; Mesnier, A.; Eljaafari, A.; Thivolet, C. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52(7):1391–1399; 2009.
34. Maitra, B.; Szekely, E.; Gjini, K.; Laughlin, M. J.; Dennis, J.; Haynesworth, S. E.; Koc, O. N. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33(6):597–604; 2004.
35. Mariani, E.; Facchini, A. Clinical applications and biosafety of human adult mesenchymal stem cells. Curr. Pharm. Des.18(13):1821–1845; 2012.
36. McCall, M.; Shapiro, A. M. Update on islet transplantation. Cold Spring Harb. Perspect. Med. 2(7):a007823; 2012.
37. Nostro, M. C.; Keller, G. Generation of beta cells from human pluripotent stem cells: Potential for regenerative medicine. Semin. Cell Dev. Biol. 23(6):701–710; 2012.
38. Pennline, K. J.; Roque-Gaffney, E.; Monahan, M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71(2):169–175; 1994.
39. Pinkerton, W.; Webber, M. A method of injecting small laboratory animals by the ophthalmic plexus route. Proc. Soc. Exp. Biol. Med. 116:959–961; 1964.
40. Pop, S. M.; Wong, C. P.; Culton, D. A.; Clarke, S. H.; Tisch, R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J. Exp. Med. 201(8):1333– 1346; 2005.
41. Sgouroudis, E.; Piccirillo, C. A. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: Lessons from mouse models and implications for human disease. Diabetes Metab. Res. Rev. 25(3):208–218; 2009.
42. Shaw, J. E.; Sicree, R. A.; Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1):4–14; 2010.
43. Suh, W. K.; Chaudhuri, J. Lymphocytes in action. Symposium on Lymphocyte Activation and Signalling. EMBO Rep. 9(9): 841–846; 2008.
44. Taghizadeh, R. R.; Cetrulo, K. J.; Cetrulo, C. L. Wharton's Jelly stem cells: Future clinical applications. Placenta 32(Suppl 4):S311–S315; 2011.
45. Tsai, P. J.; Wang, H. S.; Shyr, Y. M.; Weng, Z. C.; Tai, L. C.; Shyu, J. F.; Chen, T. H. Transplantation of insulinproducing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J. Biomed. Sci. 19:47; 2012.
46. Tse, W. T.; Pendleton, J. D.; Beyer, W. M.; Egalka, M. C.; Guinan, E. C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 75(3):389–397; 2003.
47. van Belle, T. L.; Coppieters, K. T.; von Herrath, M. G. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol. Rev. 91(1):79–118; 2011.
48. Verdaguer, J.; Schmidt, D.; Amrani, A.; Anderson, B.; Averill, N.; Santamaria, P. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186(10):1663–1676; 1997.
49. Wagner, Jr., D. H.; Vaitaitis, G.; Sanderson, R.; Poulin, M.; Dobbs, C.; Haskins, K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc. Natl. Acad. Sci. USA 99(6):3782–3787; 2002.
50. Wang, H. S.; Hung, S. C.; Peng, S. T.; Huang, C. C.; Wei, H. M.; Guo, Y. J.; Fu, Y. S.; Lai, M. C.; Chen, C. C. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22(7):1330–1337; 2004.
51. Wang, H. S.; Shyu, J. F.; Shen, W. S.; Hsu, H. C.; Chi, T. C.; Chen, C. P.; Huang, S. W.; Shyr, Y. M.; Tang, K. T.; Chen, T. H. Transplantation of insulin producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplant. 20:455–466; 2011.
52. Zhou, L.; Chong, M. M.; Littman, D. R. Plasticity of CD4+ T cell lineage differentiation. Immunity 30(5):646–655; 2009.